BlackRock
MRVI icon

BlackRock’s Maravai LifeSciences MRVI Stock Holding History

BlackRock’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.2M Buy
9,970,780
+625,512
+7% +$2.7M ﹤0.01% 2532
2026
Q1 		$26.4M Sell
9,345,268
-33,193
-0.4% -$113K ﹤0.01% 2904
2025
Q4 		$30.5M Buy
9,378,461
+274,595
+3% +$924K ﹤0.01% 2831
2025
Q3 		$26.1M Sell
9,103,866
-590,228
-6% -$1.51M ﹤0.01% 2922
2025
Q2 		$23.4M Buy
9,694,094
+145,261
+2% +$305K ﹤0.01% 2925
2025
Q1 		$21.1M Sell
9,548,833
-229,091
-2% -$905K ﹤0.01% 2898
2024
Q4 		$53.3M Sell
9,777,924
-698,159
-7% -$4.49M ﹤0.01% 2415
2024
Q3 		$87.1M Buy
10,476,083
+747,124
+8% +$6.46M ﹤0.01% 2167
2024
Q2 		$69.7M Buy
9,728,959
+3,314,335
+52% +$28.6M ﹤0.01% 2233
2024
Q1 		$55.6M Sell
6,414,624
-67,044
-1% -$454K ﹤0.01% 2379
2023
Q4 		$42.5M Buy
6,481,668
+554,360
+9% +$3.58M ﹤0.01% 2581
2023
Q3 		$59.3M Buy
5,927,308
+181,493
+3% +$1.99M ﹤0.01% 2306
2023
Q2 		$71.4M Sell
5,745,815
-154,100
-3% -$2.08M ﹤0.01% 2274
2023
Q1 		$82.7M Buy
5,899,915
+126,007
+2% +$1.81M ﹤0.01% 2135
2022
Q4 		$82.6M Buy
5,773,908
+78,397
+1% +$1.23M ﹤0.01% 2127
2022
Q3 		$145M Sell
5,695,511
-114,829
-2% -$2.88M ﹤0.01% 1710
2022
Q2 		$165M Sell
5,810,340
-171,554
-3% -$5.43M 0.01% 1668
2022
Q1 		$211M Sell
5,981,894
-71,153
-1% -$2.39M 0.01% 1637
2021
Q4 		$254M Buy
6,053,047
+1,420,288
+31% +$57.5M 0.01% 1565
2021
Q3 		$227M Buy
4,632,759
+700,552
+18% +$34.2M 0.01% 1621
2021
Q2 		$164M Buy
3,932,207
+708,029
+22% +$27.4M ﹤0.01% 1923
2021
Q1 		$115M Buy
3,224,178
+1,053,615
+49% +$34.9M ﹤0.01% 2111
2020
Q4 		$60.9M Buy
+2,170,563
New +$60.4M ﹤0.01% 2362

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's MRVI Position: Q2 2026 in Review

BlackRock increased its Maravai LifeSciences (MRVI) stake by 6.7% in Q2 2026, buying an estimated $2.7M and bringing the position to 9,970,780 shares worth $62.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

BlackRock first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $254M in Q4 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • BlackRock held 9,970,780 shares of Maravai LifeSciences worth $62.2M as of Q2 2026.
  • BlackRock bought 625,512 Maravai LifeSciences shares in Q2 2026, an estimated $2.7M.
  • Maravai LifeSciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2532 holding.
  • BlackRock first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Maravai LifeSciences position peaked at $254M in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.